JP4187277B2 - グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 - Google Patents

グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 Download PDF

Info

Publication number
JP4187277B2
JP4187277B2 JP54735198A JP54735198A JP4187277B2 JP 4187277 B2 JP4187277 B2 JP 4187277B2 JP 54735198 A JP54735198 A JP 54735198A JP 54735198 A JP54735198 A JP 54735198A JP 4187277 B2 JP4187277 B2 JP 4187277B2
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
antigen
asn
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54735198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002516610A (ja
JP2002516610A5 (enExample
Inventor
アール． フィルプラ，デイビッド
ワン，マオリャン
ジー．エル． ショー，ロバート
ディー． ウィトロー，マーク
エス． リー，リーシュン
Original Assignee
エンゾン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンゾン ファーマシューティカルズ， インコーポレイテッド filed Critical エンゾン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2002516610A publication Critical patent/JP2002516610A/ja
Publication of JP2002516610A5 publication Critical patent/JP2002516610A5/ja
Application granted granted Critical
Publication of JP4187277B2 publication Critical patent/JP4187277B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP54735198A 1997-04-30 1998-04-30 グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 Expired - Lifetime JP4187277B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4444997P 1997-04-30 1997-04-30
US60/044,449 1997-04-30
US5047297P 1997-06-23 1997-06-23
US60/050,472 1997-06-23
US6307497P 1997-10-27 1997-10-27
US60/063,074 1997-10-27
US6734197P 1997-12-02 1997-12-02
US60/067,341 1997-12-02
PCT/US1998/008662 WO1998049198A1 (en) 1997-04-30 1998-04-30 Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof

Publications (3)

Publication Number Publication Date
JP2002516610A JP2002516610A (ja) 2002-06-04
JP2002516610A5 JP2002516610A5 (enExample) 2005-12-02
JP4187277B2 true JP4187277B2 (ja) 2008-11-26

Family

ID=27488916

Family Applications (4)

Application Number Title Priority Date Filing Date
JP54735198A Expired - Lifetime JP4187277B2 (ja) 1997-04-30 1998-04-30 グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用
JP54734798A Pending JP2002505574A (ja) 1997-04-30 1998-04-30 ポリアルキレンオキシド修飾された単鎖ポリペプチド
JP2008008563A Withdrawn JP2008115193A (ja) 1997-04-30 2008-01-17 ポリアルキレンオキシド修飾された単鎖ポリペプチド
JP2009281051A Withdrawn JP2010051331A (ja) 1997-04-30 2009-12-10 ポリアルキレンオキシド修飾された単鎖ポリペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP54734798A Pending JP2002505574A (ja) 1997-04-30 1998-04-30 ポリアルキレンオキシド修飾された単鎖ポリペプチド
JP2008008563A Withdrawn JP2008115193A (ja) 1997-04-30 2008-01-17 ポリアルキレンオキシド修飾された単鎖ポリペプチド
JP2009281051A Withdrawn JP2010051331A (ja) 1997-04-30 2009-12-10 ポリアルキレンオキシド修飾された単鎖ポリペプチド

Country Status (6)

Country Link
US (8) US6323322B1 (enExample)
EP (2) EP0979102A4 (enExample)
JP (4) JP4187277B2 (enExample)
AU (2) AU7266698A (enExample)
CA (2) CA2288994C (enExample)
WO (2) WO1998049198A1 (enExample)

Families Citing this family (394)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CN1406138A (zh) * 1998-11-03 2003-03-26 塞恩托科公司 活性持续时间被增加的修饰抗体和抗体片段
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US20030027207A1 (en) * 2000-02-29 2003-02-06 Filpula David Ray Anti-platelet binding proteins and polymer conjugates containing the same
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
US6410271B1 (en) * 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US6410246B1 (en) * 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
MXPA03001469A (es) * 2000-09-08 2004-12-13 Gryphon Therapeutics Inc Proteinas sinteticas estimulantes de la eritropoyesis.
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US7195923B2 (en) * 2001-01-31 2007-03-27 Scripps Laboratories, Inc. Ratiometric determination of glycated protein
ATE432288T1 (de) 2001-02-27 2009-06-15 Maxygen Aps Neue interferon-beta-ähnliche moleküle
NZ530852A (en) 2001-08-27 2006-11-30 Genentech Inc Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2003051384A1 (en) 2001-12-17 2003-06-26 Zymogenetics, Inc. Method for treating cervical cancer
ES2561828T3 (es) 2002-01-25 2016-03-01 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
DK1517710T3 (da) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylerede faktor VII-glycoformer
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
DE60321363D1 (de) * 2002-08-28 2008-07-10 Millipore Corp Verfahren zur aufreinigung von sequenzierungsreaktionen
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1616003A4 (en) 2002-12-30 2007-06-20 Gryphon Therapeutics Inc WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
WO2004071420A2 (en) * 2003-02-05 2004-08-26 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
BRPI0408358A (pt) * 2003-03-14 2006-03-21 Neose Technologies Inc polìmeros hidrossolúveis ramificados e seus conjugados
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1624847B1 (en) * 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US9005625B2 (en) * 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
CA2534565C (en) * 2003-08-05 2012-06-19 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
US20050055024A1 (en) * 2003-09-08 2005-03-10 James Anthony H. Orthopaedic implant and screw assembly
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US20050170468A1 (en) * 2003-11-21 2005-08-04 Wenfeng Xu Anti-IL-20 receptor antibodies and binding partners and methods of using in inflammation
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
AU2009212311B8 (en) 2004-07-21 2013-05-30 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2006020372A2 (en) * 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
US20060045866A1 (en) * 2004-09-01 2006-03-02 Chris Chappelow Novel high purity and high molecular weight mPEG alcohol compositions
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
EP1836298B1 (en) 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
WO2006081249A2 (en) * 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
MX2007015058A (es) 2005-06-03 2008-01-28 Ambrx Inc Moleculas de interferon humano mejoradas y sus usos.
US8028453B2 (en) * 2005-06-16 2011-10-04 Hold That Thought, Inc. Apparatus and methods for displaying a card
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
TW200722104A (en) * 2005-06-20 2007-06-16 Pepgen Corp Low-toxicity, long-circulating human interferon-α analogs
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
WO2007021822A2 (en) * 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
ES2408581T3 (es) 2005-08-18 2013-06-21 Ambrx, Inc. Composiciones de ARNt y usos de las mismas
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090130776A1 (en) * 2005-09-01 2009-05-21 Canon Kabushiki Kaisha Binding protein molecule
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
ES2547554T3 (es) 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
CA2660310C (en) * 2006-03-30 2015-04-21 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
CA2653748A1 (en) 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
CA2653154A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
WO2008009545A1 (en) 2006-06-30 2008-01-24 Novo Nordisk A/S Anti-nkg2a antibodies and uses thereof
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
MX2009002460A (es) 2006-09-08 2009-03-20 Ambrx Inc Arnt supresor hibrido para celulas de vertebrados.
JP5840345B2 (ja) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
KR20090057383A (ko) * 2006-09-15 2009-06-05 엔존 파마슈티컬즈, 인코포레이티드 다기능성 링커를 포함하는 표적화된 고분자 전구약물
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
AU2007325838B2 (en) * 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
EP2450372B1 (en) * 2007-01-30 2015-04-22 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
EP2111228B1 (en) * 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
ES2385114T3 (es) 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
WO2009011782A2 (en) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2193146B1 (en) 2007-09-14 2016-05-25 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP2219472B1 (en) * 2007-11-15 2011-08-03 Nestec S.A. Production of food products with enhanced in mouth and mental refreshment
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
TWI468174B (zh) 2007-12-14 2015-01-11 Novo Nordisk As 針對人類ｎｋｇ２ｄ的抗體及其用途
US9097667B2 (en) * 2007-12-14 2015-08-04 Biotium, Inc. Fluorescent compounds
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
CN102007145A (zh) * 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
EP2826791A3 (en) 2008-02-20 2015-07-29 Novo Nordisk A/S Humanized anti-C5aR antibodies
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
CN106928339A (zh) 2008-07-23 2017-07-07 Ambrx 公司 经修饰的牛g‑csf多肽和其用途
CN102224238B (zh) 2008-09-26 2015-06-10 Ambrx公司 非天然氨基酸复制依赖性微生物和疫苗
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
ES2458665T5 (es) 2008-12-22 2021-06-30 Novo Nordisk As Anticuerpos contra el inhibidor de la vía del factor tisular
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US9181341B2 (en) 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
CA2766009A1 (en) * 2009-06-25 2010-12-29 Danisco A/S Variant lipolytic enzymes with improved expression, functionality and/or activity
BR112012000032A2 (pt) 2009-07-03 2016-03-15 Bionor Immuno As meios terapêuticos e diagnósticos inovadores
AU2010281453C1 (en) * 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
US8658434B2 (en) * 2009-10-28 2014-02-25 Biotium, Inc. Fluorescent pyrene compounds
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
EP2805964A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
AU2011222883B2 (en) 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
US9127052B2 (en) 2010-06-29 2015-09-08 Centre National De La Recherche Scientifique LLT-1 antibodies with new functional properties
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
EP3572091B1 (en) 2010-08-17 2023-12-13 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EP2654794B8 (en) 2010-12-22 2020-04-22 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes
CN103619877B (zh) 2011-04-21 2018-01-02 加文医学研究所 修饰的可变结构域分子及其产生和使用方法b
US20140170153A1 (en) 2011-05-31 2014-06-19 Novo Nordisk A/S Il-21 epitope and il-21 ligands
JP6141834B2 (ja) 2011-06-06 2017-06-07 ノヴォ ノルディスク アー／エス 治療抗体
AU2012268939B2 (en) 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2717917B1 (en) 2011-07-05 2016-04-20 biOasis Technologies Inc P97-antibody conjugates
WO2013011061A1 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Antagonistic antibodies against oscar
WO2013011059A1 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Antagonist antibodies against oscar
WO2013011062A2 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
WO2013011063A1 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Antagonistic antibodies against oscar
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2013120554A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
WO2013120553A1 (en) 2012-02-15 2013-08-22 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
EP2858667A1 (en) 2012-06-06 2015-04-15 Bionor Immuno AS Hiv vaccine
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
WO2014006230A1 (en) 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
AU2013296557B2 (en) 2012-07-31 2019-04-18 Bioasis Technologies Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP2890402B1 (en) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
KR20150083121A (ko) 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CA3187392A1 (en) 2013-10-15 2015-04-23 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US20160297892A1 (en) 2013-11-07 2016-10-13 Novo Nordisk A/S Novel Methods and Antibodies for Treating Coagulapathy
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015222879B2 (en) 2014-02-26 2019-12-05 The Board Of Regents Of The University Of Texas System Nitrobenzaldehyde proton release for manipulation of cellular acidosis
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EA034886B1 (ru) 2014-03-20 2020-04-02 Бристол-Майерс Сквибб Компани Связывающие сывороточный альбумин домены фибронектина iii типа
CA2952532A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
EP2975056A1 (en) 2014-07-17 2016-01-20 Novo Nordisk A/S Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
EP3026061A1 (en) 2014-11-26 2016-06-01 Novo Nordisk A/S Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
CN113214397A (zh) 2014-07-17 2021-08-06 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
JP6708635B2 (ja) 2014-10-09 2020-06-10 エンクマフ エスアーエールエル ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
CN114853868A (zh) 2014-10-24 2022-08-05 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3236994A1 (en) 2014-12-23 2017-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP6840682B2 (ja) 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
EP3313881A1 (en) 2015-06-23 2018-05-02 Innate Pharma Multispecific nk engager proteins
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
PL3331910T3 (pl) 2015-08-03 2020-05-18 Engmab Sàrl Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA)
JP6893504B2 (ja) 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン
US12102689B2 (en) 2015-11-09 2024-10-01 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
RU2018125603A (ru) 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
MA44140A (fr) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7073266B2 (ja) 2016-03-25 2022-05-23 シージェン インコーポレイテッド Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
EP3443096B1 (en) 2016-04-15 2023-03-01 Novartis AG Compositions and methods for selective expression of chimeric antigen receptors
CN113801297B (zh) 2016-04-15 2024-08-23 拜克门寇尔特公司 光敏大分子及其用途
UA127200C2 (uk) 2016-05-18 2023-06-07 Бьорінгер Інгельхайм Інтернаціональ Гмбх Молекула антитіла до pd1
WO2017203057A1 (en) 2016-05-27 2017-11-30 Alk-Abelló A/S Immunogenic proteins and fragments thereof from allergenic mites
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CN109661235B (zh) 2016-07-12 2023-05-09 凯德药业股份有限公司 抗原结合分子及其使用的方法
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3491016A1 (en) 2016-07-28 2019-06-05 Novartis AG Combination therapies of chimeric antigen receptors and pd-1 inhibitors
AU2017306267A1 (en) 2016-08-01 2019-02-14 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-M2 macrophage molecule
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US20190322767A1 (en) 2016-12-23 2019-10-24 Innate Pharma Heterodimeric antigen binding proteins
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
KR20200022447A (ko) 2017-06-27 2020-03-03 노파르티스 아게 항-tim-3 항체의 투여 요법 및 그의 용도
PE20200757A1 (es) 2017-07-11 2020-07-27 Compass Therapeutics Llc Anticuerpos agonistas que se unen a cd137 humano y sus usos
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CA3079363A1 (en) 2017-11-21 2019-05-31 Innate Pharma Multispecific antigen binding proteins
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN119220109A (zh) 2018-03-30 2024-12-31 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
EP3774902A1 (en) 2018-04-02 2021-02-17 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
CN112384534A (zh) 2018-05-21 2021-02-19 指南针制药有限责任公司 用于增强nk细胞对靶细胞的杀死的组合物和方法
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
MA52969A (fr) 2018-06-19 2021-04-28 Atarga Llc Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3813867A1 (en) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Treatment of lymmphatic metastases
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
SMT202400087T1 (it) 2018-09-11 2024-03-13 Ambrx Inc Coniugati polipeptidici di interleuchina-2 e loro usi
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
AU2019379576A1 (en) 2018-11-13 2021-06-03 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
SG11202110732XA (en) 2019-03-29 2021-10-28 Atarga Llc Anti fgf23 antibody
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
WO2021011681A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
JP2022540674A (ja) 2019-07-15 2022-09-16 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用
KR20220077127A (ko) * 2019-09-06 2022-06-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 키메라 항원 수용체 및 관련 방법 및 조성물
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
KR20220087498A (ko) 2019-10-21 2022-06-24 노파르티스 아게 Tim-3 억제제 및 그의 용도
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN113186185B (zh) * 2020-01-14 2023-05-26 东北林业大学 一种从哺乳动物粪便中高效富集宿主dna的方法
CN114980902A (zh) 2020-01-17 2022-08-30 诺华股份有限公司 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
EP4090762A1 (en) 2020-01-17 2022-11-23 Becton, Dickinson and Company Methods and compositions for single cell secretomics
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
EP4153316A1 (en) 2020-05-19 2023-03-29 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
TW202210504A (zh) 2020-05-29 2022-03-16 德國科隆大學 對抗sars相關冠狀病毒之中和抗體
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3186062A1 (en) 2020-08-10 2022-02-17 Marion BENEZECH Cell surface mica and micb detection using antibodies
TW202227449A (zh) 2020-08-20 2022-07-16 美商Ａｍｂｒｘ 公司 抗體－ｔｌｒ促效劑偶聯物、其方法及用途
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022084354A1 (en) 2020-10-21 2022-04-28 Boehringer Ingelheim International Gmbh Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
TW202233672A (zh) 2020-10-22 2022-09-01 美商健生生物科技公司 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
CN116635062A (zh) 2020-11-13 2023-08-22 诺华股份有限公司 使用表达嵌合抗原受体（car）的细胞的组合疗法
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
TW202304990A (zh) 2021-03-26 2023-02-01 美商健生生物科技公司 針對成對螺旋絲ｔａｕ之人源化抗體及其用途
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
CN117242093A (zh) 2021-04-05 2023-12-15 先天制药公司 免疫组织化学方法和kir3dl2特异性试剂
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4095156A1 (en) 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus
CA3218793A1 (en) 2021-06-09 2022-12-15 Laurent Gauthier Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
IL308531A (en) 2021-06-09 2024-01-01 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2022400238A1 (en) 2021-12-01 2024-07-11 Universität Zu Köln Neutralizing antibodies against sars-related coronavirus
EP4190810A1 (en) 2021-12-01 2023-06-07 Universität zu Köln Neutralizing antibodies against sars-related coronavirus
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023170291A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
EP4490185A1 (en) 2022-03-11 2025-01-15 JANSSEN Pharmaceutica NV Multispecific antibodies and uses thereof
AU2023232447A1 (en) 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
US20250295809A1 (en) 2022-05-13 2025-09-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CN119630747A (zh) 2022-07-01 2025-03-14 贝克曼库尔特有限公司 新的来自二氢菲衍生物的荧光染料和聚合物
EP4554677A1 (en) 2022-07-15 2025-05-21 Boehringer Ingelheim International GmbH Binding molecules for the treatment of cancer
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
KR20250067128A (ko) 2022-09-15 2025-05-14 아비디큐어 아이피 비.브이. Nk 세포의 종양-표적화를 위한 다중특이적 항원 결합 단백질 및 이의 용도
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024175802A2 (en) 2023-02-24 2024-08-29 Universität Zu Köln SARS-CoV-2 NEUTRALIZING ANTIBODIES
WO2024196805A1 (en) 2023-03-17 2024-09-26 Beckman Coulter, Inc. Benzothienopyrrole cyanine dyes
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
EP4484445A1 (en) 2023-06-26 2025-01-01 Universität zu Köln Hcmv neutralizing antibodies
WO2025003381A1 (en) 2023-06-28 2025-01-02 Universität Zu Köln Neutralizing human monoclonal antibodies against p. aeruginosa
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5202236A (en) 1984-09-13 1993-04-13 Enzon Labs Inc. Method of producing bioadhesive protein
US5049504A (en) 1986-11-24 1991-09-17 Genex Corporation Bioadhesive coding sequences
US5202256A (en) 1984-09-13 1993-04-13 Enzon Labs, Inc. Bioadhesive precursor protein expression vectors
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5212075A (en) 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5872222A (en) 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US6787153B1 (en) * 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5981273A (en) 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US6329507B1 (en) 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
EP0727992A4 (en) 1993-10-20 2001-01-31 Enzon Inc SUBSTITUTED TAXOID SUBSTANCES IN 2 'AND / OR 7' POSITION
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
NZ295673A (en) 1994-11-01 1999-03-29 Wels Wilfried Nucleic acid transfer system using recombinant multi-domain proteins each domain having a different function
WO1996040731A1 (en) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
KR19990063648A (ko) 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6025158A (en) 1997-02-21 2000-02-15 Genentech, Inc. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ATE258599T1 (de) 1997-02-21 2004-02-15 Genentech Inc Antikörperfragment-polymerkonjugate
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6323322B1 (en) * 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US6908963B2 (en) * 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
MXPA04004417A (es) * 2001-11-12 2004-08-11 Merck Patent Gmbh Anticuerpo anti-tnf alfa modificado.
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules

Also Published As

Publication number Publication date
CA2288992C (en) 2012-06-12
WO1998048837A1 (en) 1998-11-05
US20050048064A1 (en) 2005-03-03
EP0981548A1 (en) 2000-03-01
US20020061307A1 (en) 2002-05-23
US20050008650A1 (en) 2005-01-13
CA2288994A1 (en) 1998-11-05
US6872393B2 (en) 2005-03-29
AU7266898A (en) 1998-11-24
US20050042680A1 (en) 2005-02-24
AU7266698A (en) 1998-11-24
JP2010051331A (ja) 2010-03-11
EP0979102A4 (en) 2005-11-23
US6743908B2 (en) 2004-06-01
US7632504B2 (en) 2009-12-15
US6824782B2 (en) 2004-11-30
JP2002516610A (ja) 2002-06-04
US20020161201A1 (en) 2002-10-31
WO1998048837A9 (en) 1999-04-22
US20020155498A1 (en) 2002-10-24
CA2288994C (en) 2011-07-05
JP2002505574A (ja) 2002-02-19
US7150872B2 (en) 2006-12-19
CA2288992A1 (en) 1998-11-05
US6743896B2 (en) 2004-06-01
WO1998049198A1 (en) 1998-11-05
EP0979102A1 (en) 2000-02-16
JP2008115193A (ja) 2008-05-22
US20020098192A1 (en) 2002-07-25
EP0981548A4 (en) 2005-11-23
US6323322B1 (en) 2001-11-27

Similar Documents

Publication Publication Date Title
JP4187277B2 (ja) グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用
AU773568B2 (en) Antobody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin
JP5192537B2 (ja) 癌抗原ｔｍｅｆｆ２に対する抗体及びそれらの使用
US7183384B2 (en) Monoclonal antibody 7H11 reactive with human cancer
US20070199078A1 (en) Antibody fragments specific for human carcinoembryonic antigen (CEA)
ZA200305980B (en) Modified proteins, designer toxins, and methods of making thereof
CN115768797A (zh) 抗b7-h3抗体及其制备和应用
KR20060006942A (ko) 고분자 접합용 단일 사슬 항원결합성 폴리펩티드
CN113045659B (zh) 抗cd73人源化抗体
EP4279505A1 (en) Human cd276-targeting monoclonal antibody and application thereof
JP2003527334A (ja) Ａ３３抗原特異的免疫グロブリン産物を用いるａ３３抗原を発現する癌の影響を低減する方法
US20030176661A1 (en) Novel antibody with specificity for colon cancer
WO2004094612A2 (en) Cancer specific monoclonal antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080828

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080909

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110919

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120919

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130919

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term